AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection.

Research Grants 5 show all

Patents 181show all

  • 124
    C12N - Microorganisms or enzymes
  • 79
    A61K - Preparations for medical, dental, or toilet purposes
  • 74
    C07K - Peptides
  • 16
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture
  • 5
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 4
    C07C - Acyclic or carbocyclic compounds
  • 4
    C07D - Heterocyclic compounds
  • 4
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 1
    A61F - Filters implantable into blood vessels
  • 1
    A61M - Devices for introducing media into, or onto, the body

Clinical Trials 6show all

2Phase 12Phase 1/Phase 21Phase 21Phase 2/Phase 3

SEC Filings show all


231
8-K

60
10-Q

16
10-K

6
D

1
S-1

Contact Information

Richmond, VA
United States

SEC Form D Funding Events

DateOfferedSoldType
2015-03-30$13,000,000$13,000,000Equity, Option to Acquire, Security to be Acquired
2014-01-02$18,001,750$18,001,750Equity
2013-08-08$13,320,276$13,320,276Equity, Option to Acquire
2013-07-31$13,320,276$13,320,276Equity, Option to Acquire
2013-02-25$7,500,000$500,000Debt, Option to Acquire
2006-11-20Unknown Unknown Other (Paper Filing)

Key Executives

  • Philip Young
    Executive Officer
  • Jeremy Curnock Cook
    Director
  • Caroline Williams
    Director
  • Michael Perry
    Director
  • Anthony Smithyman
    Director
  • Anthony Gellert
    Director
  • Louis Drapeau
    Director
  • Kelley Wendt
    Executive Officer
  • Julian Kirk
    Director
  • Baxter Phillips, III
    Executive Officer
  • Wendy S. Johnson
    Executive Officer, Director
  • David E. Bosher
    Executive Officer
  • Baxter F. Phillips, III
    Executive Officer
  • Michael S. Perry
    Director
  • Julian P. Kirk
    Director